Publicaciones en las que colabora con Enrique Aranda Aguilar (7)

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2012

  1. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan

    Pharmacogenomics Journal, Vol. 11, Núm. 6, pp. 429-436

  2. Treatment recommendations for metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178

2007

  1. GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment

    Current Drug Metabolism, Vol. 8, Núm. 5, pp. 481-486

2006

  1. Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients

    Oncology Reports, Vol. 16, Núm. 3, pp. 497-503